The selling shareholders identified in this prospectus supplement are offering an aggregate of 30,531,917 of our ordinary shares. We are notselling any ordinary shares in this offering. We will not receive any proceeds from the sale of ordinary shares by the selling shareholders. Our ordinary shares are listed on the New York Stock Exchange (“NYSE”) under the symbol “VIK.” On May 23, 2025, the last reported shareprice of our ordinary shares as reported on the NYSE was $43.77per share. We have two classes of shares: ordinary shares and special shares. The rights of the holders of our ordinary shares and our special shares areidentical, except with respect to voting, conversion and transfer rights. Each ordinary share is entitled to one vote per share and each special share isentitled to 10 votes per share. Each special share may be converted at any time into one ordinary share at the option of the holder and will convertautomatically into one ordinary share upon transfer, subject to certain exceptions. As a result of its ownership of special shares, our principal shareholder Investing in our ordinary shares involves risks. See “Risk Factors” beginning on page S-5 of this prospectussupplement, the section entitled “Item 3.D. Key Information—Risk Factors” in our annual report on Form20-Ffor theyear ended December31, 2024 (the “2024 Annual Report”) and risks described in the other documents we have Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. We are a “foreign private issuer” under applicable SEC rules and are eligible for reduced public company disclosure requirements.The underwriters expect to deliver the ordinary shares on or about May29, 2025. J.P. Morgan BofA Securities The date of this prospectus supplement is May27, 2025. Table of Contents TABLE OF CONTENTS Prospectus Supplement Prospectus ABOUT THIS PROSPECTUSEXCHANGE CONTROL Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering andsupplements information contained in the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and theaccompanying prospectus. The second part is the accompanying prospectus, which describes more general information, some of which may not apply to Any statement made in this prospectus supplement, the accompanying prospectus or in a document incorporated by reference in this prospectussupplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in thisprospectus supplement or in any other subsequently filed document that is also incorporated or deemed to be incorporated by reference in thisprospectus supplement modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or The information contained in this prospectus supplement, the accompanying prospectus or in a document incorporated by reference in thisprospectus supplement is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement, the accompanyingprospectus or in a document incorporated by reference in this prospectus supplement or the sale of any ordinary shares. Our business, financial condition Neither we nor any selling shareholder, nor any underwriter, have authorized anyone to provide you with any information or make anyrepresentation other than the information contained in this prospectus supplement, the accompanying prospectus or any document incorporated byreference in this prospectus supplement or in any free writing prospectus supplement we may authorize to be delivered or made available to you. Neither This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the ordinary sharesdescribed in this prospectus supplement or an offer to sell or the solicitation of an offer to buy such ordinary shares in any circumstances or any For investors outside the United States: Neither we, the selling shareholders, nor any underwriter, dealer or agent have taken any action that wouldpermit the offering or possession or distribution of this prospectus supplement, the accompanying prospectus or any free writing prospectus in anyjurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of thisprospectus supplement, the accompanying prospectus or any free writing prospectus must inform themselves about, and observe any restrictions relating As used in this prospectus supplement, unless the context otherwise requires, r